Search - tctmd.com

Displaying 81 - 100 of 127

Sort: Relevancy | Date

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

Advertisement

PCSK9 Inhibitors - Are They Worth The Money?

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Evolocumab Not Cost-Effective at Current List Price

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

TCTMD’s Top 10 Most Popular Stories for May 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content